Aiosyn and Telemis advance breast cancer diagnosis with IVDR-certified AI technology

Nijmegen, the Netherlands, and Louvain-la-Neuve, Belgium — Aiosyn, a pioneering innovator in AI-powered pathology software for cancer and kidney disease, and Telemis, a specialist in medical imaging and digital pathology, today announced a partnership to enhance breast cancer grading using AI. This collaboration will enable pathologists to use Aiosyn Mitosis Breast, the first IVDR-certified tool for mitosis counting, directly within Telemis’ viewer, enhancing breast cancer grading through automated mitosis detection.

With breast cancer still the leading cause of cancer-related death among women globally, there is a pressing need for clinical tools that provide greater diagnostic consistency and efficiency. Aiosyn Mitosis Breast leverages deep learning to detect mitotic figures (cells in the process of dividing) —a critical and often subjective component of breast cancer grading—offering a scalable solution for mitosis counting to improve reproducibility and support timely treatment decisions.

Aiosyn Mitosis Breast runs in the background of the TM-Microscopy platform, analyzing whole-slide images immediately after scanning. The breast cancer diagnosis AI enables a 0-click workflow, where mitosis detection results are instantly available when pathologists open a case. This fully integrated solution helps them identify how aggressively the tumor grows while working more efficiently, especially critical amid the global shortage of pathology professionals.

Validated through a multi-center clinical study conducted in collaboration with Radboud university medical center, Aiosyn Mitosis Breast has demonstrated significant improvements in efficiency and inter-observer consistency of mitosis counting.

“At Telemis, we are convinced that artificial intelligence represents a major advance for Digital Pathology. It is essential for us that our users can benefit fully from these innovations. This is why the integration of AI is an integral part of our product roadmap. We are actively investing to improve interoperability and deliver a smooth, efficient and forward-looking experience.” David Bernard, Business Unit Manager Digital Pathology and BI, Telemis.

By combining Aiosyn’s deep-learning technology with Telemis’ Digital Pathology platform, this collaboration ensures that AI is available precisely where it delivers the most value, directly within the diagnostic workflow.

To learn more, please contact Aiosyn at [email protected] or Telemis at [email protected].

Figure 1. Automated mitotic figure identification on a breast H&E whole-slide image. Aiosyn Mitosis Breast, integrated with the Telemis TM-Microscopy solution, provides AI-powered detection and highlighting of mitotic figures in breast biopsies and resections.

About Aiosyn

Based in the Netherlands, Aiosyn develops precision pathology software for breast cancer and kidney disease, integrating its solutions into standard pathology workflows. Aiosyn has been built upon more than 20 years of research experience in the field of pathology and is rooted in pathology practice.

For full details of Aiosyn’s breast cancer diagnosis AI, visit Aiosyn Mitosis Breast.

About Telemis

Telemis is a fast growing healthcare IT company specialised in PACS/MACS (Picture/Multimedia Archiving & Communication System), Digital Pathology and Healthcare Business Intelligence solutions. Telemis develops and commercialises innovative medical imaging software and healthcare business intelligence solutions. Telemis technological solutions are integrated into customers’ existing environments, and are accompanied by local, high-quality services.

TM-Microscopy by Telemis helps to convert a laboratory into a 100% digital environment, whether for routine clinical tasks or collection.